Registry of Lobbyists
Version 1 of 69 (1996-03-25 to 1997-02-04) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Corporation: |
GLAXOSMITHKLINE
7333 MISSISSAUGA ROAD NORTH MISSISSAUGA, ON L5N 6L4 Canada |
| Telephone number: | 905-819-3030 |
| Fax number: | 905-819-3097 |
| Responsible officer name and position during the period of this registration: | PAUL N LUCAS, PRESIDENT & CEO |
| Description of activities: | GLAXO WELLCOME INC. IS ONE OF CDA'S LARGEST RESEARCH-BASED PHARMACEUTICAL CIES. IT'S BRITISH PARENT, GLAXO PLC, AMALGAMATED WITH WELLCOME PLC IN MARCH, 1995 TO CREATE THE WORLD'S LARGEST RESEEARCH-BASED PHARMACEUTICAL CIE.GLAXO WELLCOME OPERATES FOUR MAIN FACILITIES IN CDA, INCLUDING ITS BUREAU D'AFFAIRES DU QUEBEC IN MONTREAL, AND EMPLOYS MORE THAN 1100 PEOPLE ACROSS THE COUNTRY.GLAXO WELLCOME IS A LEADER IN MANY IMPORTANT THERAPEUTIC AREAS, INCLUDING CARDIOVASCULAR, GASTRO-INTESTINAL, RESPIRATORY DISEASES & ANTI-INFECTIVE.GLAXO WELLCOME INVEST MORE THAN $50 MILLION IN RESEARCH & DEV. IN CDA ANNUALLY. IN ADDDITION, GLAXO WELLCOME CONDUCTS ALMOST $10 MILLION IN CLINICAL RESEARCH ANNUALLY TO EVALUATE DRUGS FOR AIDS, ASTHMA, MIGRAINE, INFLUENZA, NAUSEA & VOMITING.GLAXO WELLCOME'S MANUFACTURING OPERATIONS SERVE BOTH CDN & AMERICAN MARKETS.GLAXO WELLCOME'S MISSISSAUGA HQ WERE COMPLETED IN 1991. THIS MARKED THE 1ST PHASE OF A MULTI-MILLION DOLLAR EXPANSION, INCLUDING A STATE-OF-THE-ART MANUFACTURING PLANT. |
| The client is a subsidiary of the following parent companies: |
GLAXO WELLCOME PLC
LANDSDOWN HOUSE, BERKELEY SQUARE LONDON W1XGBP United Kingdom |
| Coalition | The corporation is not a member of a coalition. |
| Subsidiary: | The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking. |
| Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Aboriginal Affairs and Northern Development Canada, Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Environment Canada, Federal Environmental Assessment Review Office (FEARO), Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Human Resources Development Canada (HRDC), Industry Canada, Patented Medicine Prices Review Board (PMPRB), Social Sciences and Humanities Research Council (SSHRC), Treasury Board Of Canada Secretariat (TBS), Western Economic Diversification Canada (WD) |
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format |
| Subject Matter: Areas of Concern: | Consumer Issues, Education, Employment and Training, Environment, Health, Industry, Intellectual Property, International Relations, International Trade, Regional Development, Science and Technology, Taxation and Finance |
| Subject Matter: Particulars: | ANY LEGISLATIVE PROPOSALS, POLICIES OR PAPERS, BILLS OR RESOLUTIONS, OR REGULATIONS THAT WOULD IMPACT THE BRAND NAME PHARMACEUTICAL INDUSTRY OR THE REVIEW OF ANY PATENT LEGISLATION, INLCUDING BILL C-91 |